DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on August 31, 2005; DOI: 10.1124/dmd.105.006254


0090-9556/05/3312-1811-1818$20.00
DMD 33:1811-1818, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.006254v1
33/12/1811    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamanaka, H.
Right arrow Articles by Yokoi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamanaka, H.
Right arrow Articles by Yokoi, T.

CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS

Hiroyuki Yamanaka, Miki Nakajima, Tatsuki Fukami, Haruko Sakai, Akiko Nakamura, Miki Katoh, Masataka Takamiya, Yasuhiro Aoki, and Tsuyoshi Yokoi

Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan (H.Y., M.N., T.F., H.S., A.N., M.K., T.Y.); and Department of Legal Medicine, Iwate Medical University School of Medicine, Morioka, Japan (M.T., Y.A.)

Nornicotine is an N-demethylated metabolite of nicotine. In the present study, human cytochrome P450 (P450) isoform(s) involved in nicotine N-demethylation were identified. The Eadie-Hofstee plot of nicotine N-demethylation in human liver microsomes was biphasic with high-affinity (apparent Km = 173 ± 70 µM, Vmax = 57 ± 17 pmol/min/mg) and low-affinity (apparent Km = 619 ± 68 µM, Vmax = 137 ± 6 pmol/min/mg) components. Among 13 recombinant human P450s expressed in baculovirus-infected insect cells (Supersomes), CYP2B6 exhibited the highest nicotine N-demethylase activity, followed by CYP2A6. The apparent Km values of CYP2A6 (49 ± 12 µM) and CYP2B6 (550 ± 46 µM) were close to those of high- and low-affinity components in human liver microsomes, respectively. The intrinsic clearances of CYP2A6 and CYP2B6 Supersomes were 5.1 and 12.5 nl/min/pmol P450, respectively. In addition, the intrinsic clearance of CYP2A13 expressed in Escherichia coli (44.9 nl/min/pmol P450) was higher than that of CYP2A6 expressed in E. coli (2.6 nl/min/pmol P450). Since CYP2A13 is hardly expressed in human livers, the contribution of CYP2A13 to the nicotine N-demethylation in human liver microsomes would be negligible. The nicotine N-demethylase activity in microsomes from 15 human livers at 20 µM nicotine was significantly correlated with the CYP2A6 contents (r = 0.578, p < 0.05), coumarin 7-hydroxylase activity (r = 0.802, p < 0.001), and S-mephenytoin N-demethylase activity (r = 0.694, p < 0.005). The nicotine N-demethylase activity at 100 µM nicotine was significantly correlated with the CYP2B6 contents (r = 0.677, p < 0.05) and S-mephenytoin N-demethylase activities (r = 0.740, p < 0.005). These results as well as the inhibition analyses suggested that CYP2A6 and CYP2B6 would significantly contribute to the nicotine N-demethylation at low and high substrate concentrations, respectively. The contributions of CYP2A6 and CYP2B6 would be dependent on the expression levels of these isoforms in any human liver.


Address correspondence to: Dr. Miki Nakajima, Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. E-mail: nmiki{at}kenroku.kanazawa-u.ac.jp




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Ben-Zaken Cohen, P. D. Pare, S. F. P. Man, and D. D. Sin
The Growing Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer in Women: Examining Sex Differences in Cigarette Smoke Metabolism
Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 113 - 120.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
E. Higashi, M. Nakajima, M. Katoh, S. Tokudome, and T. Yokoi
Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6
Drug Metab. Dispos., April 1, 2007; 35(4): 508 - 514.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Fukami, M. Nakajima, H. Sakai, M. Katoh, and T. Yokoi
CYP2A13 Metabolizes the Substrates of Human CYP1A2, Phenacetin, and Theophylline
Drug Metab. Dispos., March 1, 2007; 35(3): 335 - 339.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Shebley, M. I. Jushchyshyn, and P. F. Hollenberg
SELECTIVE PATHWAYS FOR THE METABOLISM OF PHENCYCLIDINE BY CYTOCHROME P450 2B ENZYMES: IDENTIFICATION OF ELECTROPHILIC METABOLITES, GLUTATHIONE, AND N-ACETYL CYSTEINE ADDUCTS
Drug Metab. Dispos., March 1, 2006; 34(3): 375 - 383.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.